2024 |
Icad Inc
|
Independent Director |
- |
- |
2024 |
Arcturus Therapeutics Holdings Inc
|
Director, Chief Financial Officer and Principal Ac |
- |
- |
2023 |
Icad Inc
|
Independent Director |
86.2 K |
-47.3 % |
2022 |
Icad Inc
|
Independent Director |
163.5 K |
-54.6 % |
2022 |
Exicure Inc
|
Director and Chief Financial Officer |
4.5 K |
-98.1 % |
2022 |
Arcturus Therapeutics Holdings Inc
|
Director and Chief Financial Officer |
- |
- |
2022 |
Exicure Inc
|
Independent Director |
- |
- |
2021 |
Icad Inc
|
Independent Director |
360.3 K |
134.1 % |
2021 |
Exicure Inc
|
Independent Director |
237.3 K |
- |
2021 |
Arcturus Therapeutics Holdings Inc
|
Director and Chief Financial Officer |
- |
- |
2020 |
Icad Inc
|
Independent Director |
153.9 K |
73.1 % |
2020 |
Arcturus Therapeutics Holdings Inc
|
Director and Chief Financial Officer |
- |
- |
2020 |
Exicure Inc
|
Independent Director |
- |
- |
2019 |
Icad Inc
|
Independent Director |
88.9 K |
68.6 % |
2019 |
MetaVia Inc.
|
- |
45.8 K |
-66.2 % |
2019 |
Arcturus Therapeutics Holdings Inc
|
Director and Chief Financial Officer |
- |
- |
2019 |
MetaVia Inc.
|
Independent Director |
- |
- |
2018 |
MetaVia Inc.
|
Independent Director |
135.6 K |
93.8 % |
2018 |
Icad Inc
|
Independent Director |
52.7 K |
9.9 % |
2018 |
Arcturus Therapeutics Holdings Inc
|
Director and Chief Financial Officer |
- |
- |
2017 |
MetaVia Inc.
|
Independent Director |
70 K |
-82.8 % |
2017 |
Icad Inc
|
Independent Director |
48.0 K |
-13.8 % |
2016 |
MetaVia Inc.
|
Independent Director |
407.3 K |
- |
2016 |
Icad Inc
|
Independent Director |
55.6 K |
272.4 % |
2015 |
Icad Inc
|
Independent Director |
14.9 K |
- |
2015 |
MetaVia Inc.
|
Independent Director |
- |
- |